Adverum Biotechnologies, Inc. (ADVM)
| Market Cap | 196.25M |
| Revenue (ttm) | 7.50M |
| Net Income (ttm) | -138.17M |
| Shares Out | 98.02M |
| EPS (ttm) | -1.45 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,334,836 |
| Open | 2.00 |
| Previous Close | 2.00 |
| Day's Range | 1.92 - 2.00 |
| 52-Week Range | 1.92 - 14.79 |
| Beta | 1.18 |
| Analysts | Buy |
| Price Target | 3.67 (+88.2%) |
| Est. Earnings Date | Nov 4, 2021 |
About ADVM
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal diseases, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was ...
Financial Performance
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for ADVM stock is "Buy." The 12-month stock price forecast is 3.67, which is an increase of 88.21% from the latest price.
News
Best Penny Stocks To Buy This Week? 10 With Potential Biotech Catalysts
Are these 10 penny stocks on your watch list this week? The post Best Penny Stocks To Buy This Week?
Adverum Presents Clinical Data on ADVM-022 at the American Society of Retina Specialists 39th Annual Scientific Meeting
-- Company maintains focus on advancing ADVM-022 at low doses in patients with wet AMD -- -- Company maintains focus on advancing ADVM-022 at low doses in patients with wet AMD --
Adverum's Single Dose Wet AMD Gene Therapy Shows Robust Two Year Durability, Safety
Adverum Biotechnologies Inc (NASDAQ: ADVM) announced new long-term data from the OPTIC trial of ADVM-022 gene therapy for neovascular or wet age-related macular degeneration (wet AMD). Data were shared ...
5 Penny Stocks To Watch This Week With Potential Biotech Catalysts
Will upcoming events mean big things for these penny stocks? The post 5 Penny Stocks To Watch This Week With Potential Biotech Catalysts appeared first on Penny Stocks to Buy, Picks, News and Informatio...
Adverum Presents 2-Year OPTIC Data Demonstrating Sustained Durability and Promising Safety Profile from Single Intrav...
-- Results featured in a presentation today at the Retina Society's 54 th Annual Scientific Meeting -- -- Robust aflibercept protein expression sustained through 2 years --
Adverum to Present Data from ADVM-022 Clinical Trials at Upcoming Medical Conferences
REDWOOD CITY, Calif., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, to...
Adverum Appoints Global Regulatory Leader Jim Wang, Ph.D., as Senior Vice President, Head of Regulatory Affairs
REDWOOD CITY, Calif., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, tod...
Why Adverum Biotechnologies (ADVM) Might Surprise This Earnings Season
Adverum Biotechnologies (ADVM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Adverum Provides Update on ADVM-022 and the INFINITY Trial in Patients with Diabetic Macular Edema
-- Based on latest analyses, company is revising ADVM-022 development plan to focus on wet AMD and low doses (2 x 10^11 vg/eye and lower); no longer planning development for DME -- -- Company to host ...
Adverum Biotechnologies (ADVM) Moves to Buy: Rationale Behind the Upgrade
Adverum Biotechnologies (ADVM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Adverum Announces Changes to Management Team
-- Christopher J. DeRespino appointed acting CFO -- -- Peter Soparkar appointed COO --
A Trio of Net Current Asset Value Stock Picks
There are some investors who invest in U.S.-listed stocks that are trading below their liquidation values because they believe they can gain from these allocations after the market has reappraised the s...
Why Adverum Biotechnologies Stock Sank in May
The uncertainty over the biotech's lead clinical asset weighed on its shares last month.
Are Options Traders Betting on a Big Move in Adverum (ADVM) Stock?
Investors need to pay close attention to Adverum (ADVM) stock based on the movements in the options market lately.
Adverum Biotechnologies (ADVM) is Oversold: Can It Recover?
Adverum Biotechnologies (ADVM) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock
Goldman Sachs Has 5 Tempting Stocks Trading Under $10 to Buy Now
While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
The Sonic Fund II, L.P. Comments on Preliminary Voting Results of Adverum Annual Meeting
HONOLULU--(BUSINESS WIRE)--The Sonic Fund II, L.P. (“Sonic”), which beneficially owns approximately 6.8% of the outstanding common stock of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) (the “Company” or...
Adverum Stockholders Re-Elect All Adverum Director Nominees at 2021 Annual Meeting
REDWOOD CITY, Calif., May 12, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, toda...
The Sonic Fund II, L.P. Issues Statement to Adverum Stockholders
HONOLULU--(BUSINESS WIRE)--The Sonic Fund II, L.P. (“Sonic”), which beneficially owns approximately 6.8% of the outstanding common stock of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) (the “Company” or...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM
NEW YORK, May 11, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Adverum Biotechnologies, Inc. ("Adverum" or the "Company") (NASDAQ: ADVM). Such investors are advi...
The Sonic Fund II, L.P. Reminds Adverum Stockholders to Vote for Its Three Independent Director Nominees at May 12 An...
HONOLULU--(BUSINESS WIRE)--The Sonic Fund II, L.P. (“Sonic”), which beneficially owns approximately 6.8% of the outstanding common stock of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) (the “Company” or...
Adverum Issues Statement Regarding Upcoming Annual Meeting of Stockholders
REDWOOD CITY, Calif., May 10, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies Inc. (“Adverum”) (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare dis...
Adverum Biotechnologies (ADVM) Reports Q1 Loss, Tops Revenue Estimates
Adverum Biotechnologies (ADVM) delivered earnings and revenue surprises of 23.68% and 1530.44%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Adverum Reports First Quarter 2021 Results
REDWOOD CITY, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, toda...
2 Falling Knives to Catch
Akebia Therapeutics Inc ( AKBA , Financial), Adverum Biotechnologies Inc ( ADVM , Financial) have performed so poorly over the prior 52 weeks through May 5, with the share prices losing more than 59%, t...